Stock analysts at StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN – Get Free Report) in a report issued on Thursday. The brokerage set a “sell” rating on the stock.
Oragenics Stock Performance
OGEN stock opened at $1.01 on Thursday. Oragenics has a one year low of $0.97 and a one year high of $7.74. The company has a market capitalization of $4.52 million, a PE ratio of -0.12 and a beta of 0.58. The stock’s fifty day moving average is $1.61.
Oragenics (NYSE:OGEN – Get Free Report) last posted its earnings results on Wednesday, May 15th. The company reported ($0.70) earnings per share for the quarter.
Institutional Inflows and Outflows
Oragenics Company Profile
Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
Featured Articles
- Five stocks we like better than Oragenics
- Canada Bond Market Holiday: How to Invest and Trade
- Stock Impact: McDonald’s Price War with Starbucks, Wendy’s
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- General Mills Q4 Sales Miss Expectations, Triggering Stock Drop
- How to Use the MarketBeat Excel Dividend Calculator
- Enovix Stock Rises 35% in Short-Squeeze: This Rally Has Legs
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.